Ask about this productRelated genes to: OVGP1 Blocking Peptide
- Gene:
- OVGP1 NIH gene
- Name:
- oviductal glycoprotein 1
- Previous symbol:
- MUC9
- Synonyms:
- CHIT5
- Chromosome:
- 1p13.2
- Locus Type:
- gene with protein product
- Date approved:
- 1996-06-12
- Date modifiied:
- 2015-11-09
Related products to: OVGP1 Blocking Peptide
Related articles to: OVGP1 Blocking Peptide
- The oviduct provides the dynamic microenvironment that supports fertilization and early embryo development yet replicating its hormonally regulated secretory activity in vitro remains a major challenge. Here, we established bovine oviductal epithelial organoids that exhibit a polarized epithelial organization and endocrine responsiveness, while recapitulating key features of the native oviduct. Exposure to either estradiol or progesterone resulted in distinct transcriptomic and proteomic landscapes that were characteristic of the follicular and luteal phases, respectively. This included the upregulation of canonical phase-specific markers, such as OVGP1, NTS, HP and TGM2. Proteomic profiling of organoid-derived secretions (ODS) revealed extensive overlap with in vivo oviductal fluid. Integration of transcriptomic and proteomic datasets by multi-omics factor analysis identified coherent biological signatures defining each hormonal state. Functionally, ODS obtained from estradiol-treated organoids enhanced sperm capacitation and acrosome reaction, recapitulating the activity of follicular-phase oviductal fluid. These findings demonstrate that hormonally responsive oviductal organoids generate bioactive secretions that emulate the molecular and functional features of the native oviductal environment, providing a sustainable and physiologically relevant platform for studying gamete-maternal communication and improving assisted reproduction technologies. - Source: PubMed
Publication date: 2026/04/21
Navarro-Serna SergioRomero-Aguirregomezcorta JonHernández-Díaz NathalyFerrero-Micó AnaCoy PilarPérez-García Vicente - Preclinical mouse models for ovarian cancer that faithfully recapitulate human disease on both histopathological and molecular levels are crucial for advancing novel interventions into the clinic. We developed three genetically engineered mouse (GEM) models for fallopian tube-originating ovarian cancer with the loss of Brca1, Trp53, and Rb expression driven by or promoters or virally induced directly in the oviductal epithelium. We profiled the tumors by histology and gene expression and compared them to a previously described ovarian cancer model derived from ovarian surface epithelium. Expression profiles from the oviductal and ovarian epithelium tumors fall within the four subtypes of human high-grade serous carcinoma (HGSC) and represent different patient subpopulations. Allograft tumor models derived from the GEMs are amenable to preclinical intervention studies and respond to standard of care therapies. These well-defined, tractable models present a valuable resource for assessing novel drugs and immunotherapies for patients with HGSC. - Source: PubMed
Publication date: 2025/11/26
Szabova LudmilaLu LucyGordon Melanie BJohnson KristineGuerin Theresa MBassel LauraHouseholder Deborah BEdouard MargalieRies AmyKozlov SergueiCollins N KeithCuster WendiCho KathleenSamimi GoliShoemaker Robert HWeaver Ohler Zoe - Oviduct glycoprotein 1 (OVGP1) is a key protein involved in oviductal functions. β-estradiol (E) and progesterone (P), oxytocin (OXT) and tumor necrosis factor-α (TNFα) modulate the equine oviduct function, through prostaglandin regulation. The objective was to evaluate OVGP1 expression within each equine oviduct segment (infundibulum, ampulla isthmus), throughout the estrous cycle. The in vitro effect of (i) E, P, OXT, TNFα; and (ii) spermatozoa, on oviduct OVGP1 transcription and secretion was studied. Gene transcription was assessed by real-time PCR; protein expression by western blot; and protein production by enzyme immunoassay. OVGP1 mRNA increased in the ampulla, in the early-luteal phase (P < 0.05). OVGP1 protein expression increased in the follicular phase, in all portions (P < 0.05). A temporal desynchronization between transcription and protein synthesis might maintain oviduct function. In ampulla explants, OXT and TNFα up-regulated OVGP1 transcripts in follicular phase; E in early-luteal phase; and P in mid-luteal phase (P < 0.05). OXT and TNFα effect on OVGP1 transcripts might be ascribed to prostaglandin modulation. Oviductal endogenous E in follicular phase, could prime E stimulation of OVGP1 transcripts in early-luteal phase. The stimulatory effect of P on OVGP1 transcripts may modulate early embryogenesis. OVGP1 in vitro production was not dependent of E, P, OXT or TNFα treatments. Sperm cells, either in direct or indirect contact with oviduct explants, up-regulated OVGP1 production, in the isthmus (P < 0.05). These data suggest that OVGP1 modulates sperm and mare's oviduct cross-talk and may play an important role in improving assisted reproductive technologies. - Source: PubMed
Publication date: 2025/12/11
Pinto-Bravo PedroRebordão Maria RosaAmaral Ana SSzóstek-Mioduchowska AnnaFernandes CarinaGalvão António MSilva ElisabeteAlpoim-Moreira Joanada Costa Rosário P RobertoSkarzynski Dariusz JFerreira-Dias Graça M - The zona pellucida (ZP) is a glycoprotein-rich extracellular matrix essential for fertilization, early embryonic development, and implantation. Beyond its core functions, the ZP undergoes dynamic remodeling during oocyte maturation, involving regulated synthesis, assembly, and conformational changes. This complex and tightly controlled process ensures the biomechanical integrity of the oocyte, providing both protection and selective permeability essential for reproductive success. Oviductal glycoprotein 1 (OVGP1; oviductin) integrates into the ZP, modulating pore size, glycan composition, and structural homogeneity. This glycoprotein establishes a species-specific barrier that prevents polyspermy and fine-tunes sperm-oocyte interactions. Recent evidence suggests that OVGP1 not only contributes to ZP stabilization but also influences sperm capacitation, acrosome reaction, and early zygotic signaling, thereby linking oviductal physiology to gamete compatibility. Exploiting ZP remodeling in assisted reproductive technologies (ART) offers new opportunities to enhance fertilization efficiency, embryo quality, and implantation success, including through assisted hatching or modulating ZP properties to overcome fertility limitations. Moreover, advances in proteomic and glycomic profiling of the ZP are enabling the identification of novel biomarkers of oocyte competence and reproductive potential. These advances provide critical insights into species-specific reproductive mechanisms and pave the way for improved ART protocols and fertility preservation strategies. - Source: PubMed
Publication date: 2025/11/17
de la Fuente DanielPrestianni MichelaNavarrete-López PaulaGarcía-Merino CristinaBalastegui-Alarcón MiriamSoria PilarAvilés ManuelRizos DimitriosGutiérrez-Adan Alfonso - BACKGROUND: Polycystic ovary syndrome (PCOS) is one of the most common endocrine disorders, affecting 8–13% of women of reproductive age. Its heterogeneous presentation and the variability of diagnostic criteria make accurate diagnosis and effective management challenging. Artificial intelligence (AI) methods, including machine learning (ML), deep learning (DL), explainable AI (XAI), and large language models (LLMs), have recently emerged as promising approaches to address these gaps. OBJECTIVE: This systematic review aimed to provide a comprehensive synthesis of AI applications in PCOS, with emphasis on diagnostic performance, biomarker discovery, risk prediction, clinical decision support, model interpretability, and the emerging use of generative AI. METHODS: Following PRISMA 2020 guidelines, PubMed, Scopus, and Web of Science were searched from inception to March 2025. Eligible studies applied AI techniques to PCOS and reported at least one performance metric. Two reviewers independently screened and extracted data, with quality appraisal conducted using QUADAS-2 and ROBIS. Given the heterogeneity of designs and outcomes, findings were narratively synthesized across imaging, clinical/EHR, and biomarker/-omics domains. RESULTS: From 662 retrieved records, 80 studies met the inclusion criteria. CNN-based models dominated imaging applications, with accuracies often exceeding 95% and occasionally reaching 98–99%. Supervised ML approaches, particularly random forests and support vector machines, achieved consistent high performance in clinical and biochemical datasets. Omics-based studies revealed novel biomarkers such as HDDC3, SDC2, MAP1LC3A, and OVGP1. However, only about one-quarter of studies applied XAI methods, limiting transparency and clinical trust. Early evaluations of LLMs suggested potential for patient education and decision support but highlighted risks of bias, hallucination, and lack of domain-specific training. Key limitations across studies included small sample sizes, class imbalance, methodological heterogeneity, and limited external validation. CONCLUSIONS: AI offers substantial opportunities to advance PCOS diagnosis and prediction by integrating multimodal data and reducing diagnostic subjectivity. Yet its clinical adoption is constrained by interpretability gaps and insufficient validation. Future priorities include large multicenter studies, standardized reporting, systematic use of XAI, and careful evaluation of LLMs to ensure safe, equitable, and clinically meaningful integration into PCOS care. - Source: PubMed
Publication date: 2025/11/24
Ghaderzadeh MustafaGaravand AliSalehnasab Cirruse